drugset / Trial / NCT00137852

Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer

NCT00137852 ↗

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a study for patients with resectable, locally advanced esophageal cancer. There is evidence to suggest that celecoxib in combination with cisplatin and irinotecan (CPT-11) may work well with radiation therapy to kill cancer cells. The primary goal is to develop a well-tolerated cancer treatment that has an acceptable response rate.

Timeline

Start
2002-01
Primary completion
2004-08
Completion
2017-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Celecoxib Other / unclassified 400 mg Oral
Subject Cisplatin Other / unclassified 30 mg/m2 —
Subject Irinotecan Small molecule 65 mg/m2 —

Indications